Login   Contact Us      

Improve Your Reimbursement Results

Serum versus Plasma

Take Control of Your Medicare A/R

Staff Feedback Pays Dividends

Boost Cash Flow by Tracking DSO

Pharmacy Quality Standards

Billing Specialists Get The Job Done

Should you Part D

The Right Team Makes A Great Company

The Importance of Proper Aseptic Technique

The Answers Are in Your Data

Synercid

Inside the 835 - Part 1 - CR Codes

Treating an Unhealthy Accounts Receivable

Are You Compounding or Manufacturing?

Prepare For Bad Debt Reserves

Maximizing Your Value in Mergers and Acquisitions

Is Outsourcing Right For You?

Team Talent is Essential

What's the Value of Your Business

Inside the 835: Part 2--Medicare Codes

Pharmacists Recognized As A Provider:

Part D Success Story: $24K Denied, Then Reversed

Maximize Revenue On Rental Equipment

Leverage Points: Mission and Vision

The Value of Therapeutic Drug Monitoring

Listserv Lessons: Post-dose Vancomycin peak draws

Take Control of Your Patient Receivables

Acquisition Strategy – Securing Management

Pedigree Provisions: A New Responsibility

Cash is still King

Listserv Lessons: Patient Financial Responsibility

HEMOLYSIS - CAUSE AND EFFECT

Who's tracking YOUR sales?

Five Approaches to Training a Sales Person

CASH FLOW: Shows Your Company’s True Health

NPI Deadline is May 23 - Are you ready?

Listserv Lessons: Billing Per Diems on Non-Infused

Microalbumin

Credit Balances, an overlooked problem

Managing Open Invoices

Listserv Lessons: Insurance Company defining AWP

Revenue Recognition: Are You Collecting 95%?

BitLeap's online, offsite data backup system

Is NHIC getting The Job Done?

Drug of the Month - Infliximab

Sed.Rate and C-Reative Protein Assay

A Systemic Approach to Purchasing Negotiations

A Systemic Approach to Purchasing Negotiations 2

Practical Approach to Physician Credentialing

Is Noridian Getting The Job Done?

The Pharmacist’s Awareness of “Drug Induced Diseas

Listserv Lessons: Medicare Billing Split between M

Glycosylated Hemoglobin

Drug of the Month – Daptomycin (Cubicin®)

Using Denial Tracking to Improve Cash Flow and Sta

Dealing with Denial Code 204 (Replacment for PR 96

The Medicare Program: A Brief Overview

ListServ Lessons: Power PICC Flushing Protocols

Can a blood test predict a heart attack?

Software Implementations - do it perfect the first

Drug of the Month – Lynezolid (Zyvox®)

Add a second monitor to your laptop / desktop

Software implementations – it’s a great time to be

Extreme Drug-Resistant Tuberculosis

Listserv Lessons: Home Infusion Pharmacy vs Specia

Patient Satisfaction Scores

Managing your payer pricing files

Leadership: An Analysis

Listserv Lessons: Enteral Practice Standards

MRSA on the Rise

Using Clinicians to Improve Reimbursement

Software Implementations: Multi-site conversions

System Management: Managing Serialized Inventory

So, you have a payer contract…or do you?

Questions and Answers about Lyme Disease

Listserv Lessons: Timely Filing and Patient Debt O

System Implementation: 5 Phases of Information Sy

Managing your Windows Desktop

Insurance Companies Play to Win ... you should too

Blood Culture Contamination

KVO’s on Intermittent Pump Infusions

So, the nice lady at Medicare told you that it wou

Listserv Lessons: Huber Needle Changes

ListServ Lessons: Compounding Question

How many billers necessary to change a light bulb?

Listserv Lessons: Monitoring Shipping

Use of Routine ABNs

Investigating Reimbursement Issues

Repackaging your managed care strategy

Managing your Shared Contract Files

Stale A/R on Legacy Systems – Is It Really Worth I

ListServ Lessons - Infusion of Specialty Meds

Know Who Your Patients Are and Where They Are Comi

Know who your patients are and where they are comi

Patient Pay Accounts - If you can't measure it, yo

Those Pesky Rascals

The Care and Feeding of Your Item Master File

Billing Staff Measurement and Feedback

This Call May be Monitored for Quality Assurance

The Price is Right…Or Maybe Not

Using Time & Motion Studies to Improve Pharmacy Pr

What's the Value of Your Business

By Nishen Radia
Monday, October 16, 2006

What’s the Value of Your Business?
By Nishen Radia, FocalPoint Partners, LLC

In this month’s Rock-Pond article, we discuss the key issues any entrepreneur should understand when assessing the valuation of their healthcare assets.

 

Time and time again, entrepreneurs, when considering their exit options for their business, ask us the same question:  “How much is my business worth?”  And the answers we give every time are exactly the same: more questions right back at you! All businesses are not created equal!

Valuation is an art, and not a science. This is particularly the case when thinking about home healthcare providers, where the quality of business and operations can have deep impacts on valuation.  Some of these factors can be controlled, some can’t. Yet acquirors often revert blindly to “industry multiples”. But as recent deals have shown, the right asset positioned correctly can optimize valuation and blow industry averages away!

So, what drives valuation and what does this tell us about how to position a company? Firstly, growth is key. The reason why specialty businesses trade at strong multiples is the scaleability and growth.  As an entrepreneur, always map out your growth strategy. Being able to demonstrate where the company is going and how you’ve executed on previous years’ strategies will be critical in driving valuation.  Tied to growth, the second factor is profitability. Margins remain key, so make sure that growth is profitable.

You’ve all heard that in real estate, the key is location, location, location. When valuing companies, the key is management, management, management. A company with well-run operations, strong sales and marketing and tight financial controls will always be valued at higher multiples. A strong management team will allow a buyer to have greater confidence in the target’s growth. 

These factors are applicable to all companies.  Home healthcare providers face an additional burden in demonstrating why they should be valued higher. There are a number of other factors that need consideration. A well-diversified payor mix is key, as significant payor concentration vastly increases the risk to a buyer.  Billing and collection are highly relevant. Every deal we have closed at FocalPoint in the healthcare space has involved buyers spending time poring over cash collection schedules. To the extent a company is not collecting over time, the buyer will start to discount revenues and profitability.

Healthcare entrepreneurs must continually innovate to remain in line with industry trends. The recent advent of ambulatory infusion suites (“AISs”) is an example.  Entrepreneurs that had a cohesive, robust strategy for AISs were rewarded by buyers who valued the initiative to stay ahead of the curve in an ever-changing healthcare environment.

Finally, there are a whole set of factors an entrepreneur just cannot control. Geography is critical – buyers see certain markets as more strategic than others. That cycle of focus is constantly evolving and should be less of a worry to entrepreneurs. Macroeconomics and capital markets will affect value. We are in one of the best M&A markets of recent times for a simple reason—buyers have been given extra confidence by relaxed capital markets and an economy that has been strong. That has driven many of the high valuation’s we’ve been seeing recently. Beware – it won’t last forever!

 


Download Article

Nishen Radia


Nishen Radia is a co-founder of FocalPoint Partners, and has years of experience advising middle-market and multinational corporations on merger and acquisition strategies and execution, debt and equity capital raising and valuation/fairness opinions. Since co-founding FocalPoint, Mr. Radia has closed numerous transactions in the US middle-market, where he has applied the technical expertise and know-how gained working with larger firms to his more entrepreneurial client base.

View all articles by Nishen Radia


FocalPoint Partners, LLC


FocalPoint Partners LLC is an independent investment bank, specializing in mergers and acquisitions (both healthy and distressed), private placements (both debt and equity), and financial restructurings. The firm’s primary focus is on middle-market companies with revenues between $10 million and $250 million in a diverse range of industries. The firm’s goal is to provide unbiased, innovative financial advice by taking the time to truly understand the needs of its clients and then devising a strategy that best fits those objectives.

View all articles by FocalPoint Partners, LLC

 
 


Copyright © 2010 Rock-Pond Solutions. All Rights Reserved.